>>Description of the research protocol "Registre Adcetris"

National registry to evaluate real-life use of Adcetris (brentuximab vedotin) in Belgium
Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Hémato-onco
Brugmann identifier : Registre Adcetris
EudraCT identifier : B322201422906


Involved department : Hemato-oncology
Principal investigator : Nifosi/Efira
Sponsor : Takeda
Contact : Clinical Research Unit

>This protocol was approved by the KU Leuven ethics committee.